Cargando…
A Multiscale, Systems-Level, Neuropharmacological Model of Cortico-Basal Ganglia System for Arm Reaching Under Normal, Parkinsonian, and Levodopa Medication Conditions
In order to understand the link between substantia nigra pars compacta (SNc) cell loss and Parkinson's disease (PD) symptoms, we developed a multiscale computational model that can replicate the symptoms at the behavioural level by incorporating the key cellular and molecular mechanisms underly...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8762321/ https://www.ncbi.nlm.nih.gov/pubmed/35046787 http://dx.doi.org/10.3389/fncom.2021.756881 |
_version_ | 1784633737182445568 |
---|---|
author | Nair, Sandeep Sathyanandan Muddapu, Vignayanandam Ravindernath Chakravarthy, V. Srinivasa |
author_facet | Nair, Sandeep Sathyanandan Muddapu, Vignayanandam Ravindernath Chakravarthy, V. Srinivasa |
author_sort | Nair, Sandeep Sathyanandan |
collection | PubMed |
description | In order to understand the link between substantia nigra pars compacta (SNc) cell loss and Parkinson's disease (PD) symptoms, we developed a multiscale computational model that can replicate the symptoms at the behavioural level by incorporating the key cellular and molecular mechanisms underlying PD pathology. There is a modelling tradition that links dopamine to reward and uses reinforcement learning (RL) concepts to model the basal ganglia. In our model, we replace the abstract representations of reward with the realistic variable of extracellular DA released by a network of SNc cells and incorporate it in the RL-based behavioural model, which simulates the arm reaching task. Our results successfully replicated the impact of SNc cell loss and levodopa (L-DOPA) medication on reaching performance. It also shows the side effects of medication, such as wearing off and peak dosage dyskinesias. The model demonstrates how differential dopaminergic axonal degeneration in basal ganglia results in various cardinal symptoms of PD. It was able to predict the optimum L-DOPA medication dosage for varying degrees of cell loss. The proposed model has a potential clinical application where drug dosage can be optimised as per patient characteristics. |
format | Online Article Text |
id | pubmed-8762321 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-87623212022-01-18 A Multiscale, Systems-Level, Neuropharmacological Model of Cortico-Basal Ganglia System for Arm Reaching Under Normal, Parkinsonian, and Levodopa Medication Conditions Nair, Sandeep Sathyanandan Muddapu, Vignayanandam Ravindernath Chakravarthy, V. Srinivasa Front Comput Neurosci Neuroscience In order to understand the link between substantia nigra pars compacta (SNc) cell loss and Parkinson's disease (PD) symptoms, we developed a multiscale computational model that can replicate the symptoms at the behavioural level by incorporating the key cellular and molecular mechanisms underlying PD pathology. There is a modelling tradition that links dopamine to reward and uses reinforcement learning (RL) concepts to model the basal ganglia. In our model, we replace the abstract representations of reward with the realistic variable of extracellular DA released by a network of SNc cells and incorporate it in the RL-based behavioural model, which simulates the arm reaching task. Our results successfully replicated the impact of SNc cell loss and levodopa (L-DOPA) medication on reaching performance. It also shows the side effects of medication, such as wearing off and peak dosage dyskinesias. The model demonstrates how differential dopaminergic axonal degeneration in basal ganglia results in various cardinal symptoms of PD. It was able to predict the optimum L-DOPA medication dosage for varying degrees of cell loss. The proposed model has a potential clinical application where drug dosage can be optimised as per patient characteristics. Frontiers Media S.A. 2022-01-03 /pmc/articles/PMC8762321/ /pubmed/35046787 http://dx.doi.org/10.3389/fncom.2021.756881 Text en Copyright © 2022 Nair, Muddapu and Chakravarthy. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Neuroscience Nair, Sandeep Sathyanandan Muddapu, Vignayanandam Ravindernath Chakravarthy, V. Srinivasa A Multiscale, Systems-Level, Neuropharmacological Model of Cortico-Basal Ganglia System for Arm Reaching Under Normal, Parkinsonian, and Levodopa Medication Conditions |
title | A Multiscale, Systems-Level, Neuropharmacological Model of Cortico-Basal Ganglia System for Arm Reaching Under Normal, Parkinsonian, and Levodopa Medication Conditions |
title_full | A Multiscale, Systems-Level, Neuropharmacological Model of Cortico-Basal Ganglia System for Arm Reaching Under Normal, Parkinsonian, and Levodopa Medication Conditions |
title_fullStr | A Multiscale, Systems-Level, Neuropharmacological Model of Cortico-Basal Ganglia System for Arm Reaching Under Normal, Parkinsonian, and Levodopa Medication Conditions |
title_full_unstemmed | A Multiscale, Systems-Level, Neuropharmacological Model of Cortico-Basal Ganglia System for Arm Reaching Under Normal, Parkinsonian, and Levodopa Medication Conditions |
title_short | A Multiscale, Systems-Level, Neuropharmacological Model of Cortico-Basal Ganglia System for Arm Reaching Under Normal, Parkinsonian, and Levodopa Medication Conditions |
title_sort | multiscale, systems-level, neuropharmacological model of cortico-basal ganglia system for arm reaching under normal, parkinsonian, and levodopa medication conditions |
topic | Neuroscience |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8762321/ https://www.ncbi.nlm.nih.gov/pubmed/35046787 http://dx.doi.org/10.3389/fncom.2021.756881 |
work_keys_str_mv | AT nairsandeepsathyanandan amultiscalesystemslevelneuropharmacologicalmodelofcorticobasalgangliasystemforarmreachingundernormalparkinsonianandlevodopamedicationconditions AT muddapuvignayanandamravindernath amultiscalesystemslevelneuropharmacologicalmodelofcorticobasalgangliasystemforarmreachingundernormalparkinsonianandlevodopamedicationconditions AT chakravarthyvsrinivasa amultiscalesystemslevelneuropharmacologicalmodelofcorticobasalgangliasystemforarmreachingundernormalparkinsonianandlevodopamedicationconditions AT nairsandeepsathyanandan multiscalesystemslevelneuropharmacologicalmodelofcorticobasalgangliasystemforarmreachingundernormalparkinsonianandlevodopamedicationconditions AT muddapuvignayanandamravindernath multiscalesystemslevelneuropharmacologicalmodelofcorticobasalgangliasystemforarmreachingundernormalparkinsonianandlevodopamedicationconditions AT chakravarthyvsrinivasa multiscalesystemslevelneuropharmacologicalmodelofcorticobasalgangliasystemforarmreachingundernormalparkinsonianandlevodopamedicationconditions |